Management of Acute Severe Colitis with Pericolic Fluid

Initial Assessment & Risk Stratification

Pericolic fluid on CT is a marker of severe colonic inflammation that warrants immediate inpatient care and consideration of surgical consultation. 1
Hospitalization criteria for acute severe colitis include temperature > 37.8 °C, heart rate > 90 bpm, hemoglobin < 105 g/L, or CRP > 30 mg/L. 1
≥ 6 bloody stools per day together with any systemic toxicity fulfills the definition of acute severe ulcerative colitis (ASUC). 1
Presence of peritoneal signs (severe abdominal pain, rebound tenderness, guarding, or hypoactive bowel sounds) indicates possible complications and triggers emergency surgical evaluation. 2
CT features predictive of higher mortality: colonic wall thickness > 4 mm, pericolic fat stranding, ascites, pneumatosis intestinalis, or free intra‑abdominal air. 2

Diagnostic Workup

Baseline laboratory panel before therapy should include complete blood count, CRP, urea/electrolytes, liver function tests, magnesium, and albumin. 1
Stool investigations must cover bacterial cultures (Salmonella, Shigella, Campylobacter, E. coli), C. difficile toxin assay, and ova/parasites when indicated. 1
Treatment must not be delayed while awaiting stool culture results if ASUC is suspected. 1
Flexible sigmoidoscopy within 48 h is recommended to obtain biopsies for histology, assess for CMV infection, and identify deep ulceration (a poor‑prognosis marker). 1
Full colonoscopy should be avoided in fulminant colitis because of a heightened perforation risk. 2

Therapeutic Management – Acute Severe Ulcerative Colitis

Initiate intravenous corticosteroids immediately: hydrocortisone 100 mg every 6 h or methylprednisolone 60–80 mg daily. 1
Provide thromboprophylaxis with low‑molecular‑weight heparin for all admitted patients. 1
Withhold 5‑ASA agents during the acute phase. 1
Conduct daily senior gastroenterology review, repeat labs (FBC, U&E, CRP), and surgical assessment if systemic toxicity persists. 1
Day‑3 response assessment: > 8 bowel movements/day or 3–8 movements/day with CRP > 45 mg/L predicts an ~85 % chance of steroid failure, indicating the need for rescue therapy (infliximab or cyclosporine). 1

Special Situations

Suspected or Confirmed Clostridioides difficile

Empiric oral vancomycin 125 mg four times daily for 10 days is advised while awaiting test results in severe presentations. 2
Discontinue any inciting antibiotics whenever feasible. 2
If C. difficile is confirmed and the patient is already on steroids, add oral vancomycin 500 mg every 6 h for 10 days while continuing corticosteroids. 1

Non‑C. difficile Infectious Colitis

Stop unnecessary antibiotics promptly to reduce recurrence risk. 3
Provide supportive care with intravenous fluids, potassium and magnesium replacement, and maintain hemoglobin > 10 g/dL. 4

Ischemic Colitis

Conservative management (bowel rest, IV fluids, broad‑spectrum antibiotics) is first‑line.
Ultrasound‑measured bowel wall thickness > 10 mm is associated with a 60 % mortality rate versus 4.2 % when ≤ 10 mm. 5

Supportive Care Measures

Correct dehydration and replace potassium and magnesium losses. 4
Initiate enteral or parenteral nutrition when malnutrition is present. 4
Avoid antiperistaltic agents and opiates to prevent toxic megacolon. 6
Perform daily abdominal examinations; obtain imaging if transverse colon diameter exceeds 5.5 cm. 4

Indications for Emergency Surgical Consultation

Radiographic free air indicating colonic perforation. 2
Toxic megacolon (radiologic colonic dilation with severe systemic inflammation). 6
Hemodynamic instability or septic shock despite optimal medical therapy. 2
Severe ileus manifested by vomiting, absent stool passage, and markedly dilated bowel loops. 6
Clinical deterioration after 3–5 days of maximal medical treatment. 1
Serum lactate > 5.0 mmol/L, a marker of severe disease warranting urgent colectomy. 6

Prognostic Factors & Outcomes

Low hemoglobin, albumin < 30 g/L, and elevated lactate are linked to higher rates of surgery, ICU admission, and mortality. 1
Endoscopic deep ulceration predicts poorer outcomes and increased colectomy rates. 1
A CRP/albumin ratio > 0.85 combined with stool frequency > 3 per day confers a 74 % risk of treatment failure. 1
Presence of pericolic fluid together with distant free air carries a 57–60 % failure rate with conservative management, often necessitating surgery. 7

Treatment of Colitis

Initial Evaluation

The initial treatment for a patient with diarrhea and colitis identified on CT scan should focus on determining the specific cause of colitis through appropriate diagnostic testing before initiating targeted therapy 8, 9
A comprehensive stool workup is recommended, including stool tests for Clostridioides difficile toxin 10, 9, 11
Stool cultures for bacterial pathogens, such as Salmonella, Shigella, Campylobacter, and E. coli, should be performed 9
Tests for ova and parasites should be considered if clinically indicated 9
Stool inflammatory markers, such as lactoferrin and calprotectin, can assess inflammation severity 8, 12
Laboratory tests, including complete blood count, C-reactive protein, erythrocyte sedimentation rate, electrolytes, liver enzymes, and renal function, should be conducted 8, 9, 13
CMV testing should be considered, especially in immunocompromised patients 8, 13

Diagnostic Considerations

CT findings of colitis typically include colonic wall thickening, peri-colonic stranding, and sometimes ascites 10, 11
Endoscopic evaluation with flexible sigmoidoscopy or colonoscopy with biopsies should be considered if stool inflammatory markers are elevated 14, 12
Endoscopic evaluation should also be considered if symptoms persist despite initial treatment 9, 13
Endoscopic evaluation can help differentiate between infectious, inflammatory, or ischemic colitis 10, 11

Treatment Algorithm

For suspected C. difficile colitis, oral vancomycin or fidaxomicin is the preferred initial treatment 10, 11
For other bacterial causes, targeted antibiotic therapy based on culture results should be used 9
For mild to moderate ulcerative colitis, oral mesalamine and topical mesalamine should be started 12
For moderate to severe IBD colitis, systemic corticosteroids and biologic therapy with infliximab or vedolizumab may be necessary 8, 12
For immune checkpoint inhibitor-related colitis, a low-fiber diet and close monitoring should be used for grade 1 symptoms 15, 16
For grade 2 or higher immune checkpoint inhibitor-related colitis, systemic corticosteroids and infliximab may be necessary 8, 15, 16

Supportive Care

Adequate hydration and electrolyte replacement are essential for all patients 8, 9
Temporary bowel rest may be considered in moderate to severe cases 12
NSAIDs should be avoided as they can exacerbate colonic inflammation 12
Loperamide may be used cautiously for mild diarrhea without infectious cause 14

Warning Signs

Severe abdominal pain, fever, or signs of peritonitis require urgent intervention 10, 13
Significant rectal bleeding requires urgent intervention 13, 12
Evidence of bowel perforation or toxic megacolon on imaging requires urgent intervention 8, 10

Follow-up

Clinical response should be monitored through symptom assessment and inflammatory markers 9, 12
Follow-up endoscopy may be necessary to confirm mucosal healing in moderate to severe cases 12
Maintenance therapy should be used to prevent relapses in IBD patients 12

Guideline Summary for CT‑Identified Inflammatory Colitis: Evidence‑Based Diagnostic and Management Recommendations

Diagnostic Workup

Imaging‑Based Etiology Clues

Endoscopic Evaluation Strategy

Management of Immune Checkpoint Inhibitor (ICI)‑Related Colitis

Limitations of CT Imaging

All statements are supported by the cited peer‑reviewed literature.

Management of Acute Severe Colitis with CT‑Confirmed Findings

Admission & Immediate Risk Stratification

Hospitalize any patient who meets acute severe colitis criteria (≥ 6 bloody stools per day and temperature > 37.8 °C, heart rate > 90 bpm, hemoglobin < 105 g/L, or CRP > 30 mg/L) and admit for inpatient care with immediate IV corticosteroids, urgent stool studies, and flexible sigmoidoscopy within 48 h; involve surgery early if peritoneal signs, toxic megacolon, or pericolic fluid are present. 23

Diagnostic Workup (Do Not Delay Treatment)

Obtain baseline laboratory panel on admission—including complete blood count, CRP, urea/electrolytes, liver function tests, magnesium, and albumin—to guide severity assessment. 23
Send comprehensive stool studies for bacterial pathogens (e.g., Salmonella, Shigella, Campylobacter, E. coli), Clostridioides difficile toxin assay, and ova/parasites; however, do not wait for results before initiating therapy when acute severe colitis is suspected. 23
Perform flexible sigmoidoscopy within 48 h to obtain biopsies for histology, assess for CMV infection (especially in immunocompromised patients), and identify deep ulceration, a marker of poor prognosis. 23
Avoid full colonoscopy in fulminant colitis because of a heightened risk of perforation. [23][24]

Initial Medical Management

Start IV corticosteroids after fluid resuscitation: hydrocortisone 100 mg every 6 h or methylprednisolone 60–80 mg daily. 23
Provide pharmacologic thromboprophylaxis with low‑molecular‑weight heparin for all admitted patients; rectal bleeding is not a contraindication. 23
Correct dehydration and replace potassium (≥ 60 mmol/day) and magnesium losses to prevent hypokalaemia and toxic colonic dilatation. 23

Daily Monitoring & Early Response Assessment

Conduct daily senior gastroenterology review, repeat laboratory tests (CBC, U&E, CRP), and perform daily abdominal examinations. 23
On day 3, assess response: > 8 bowel movements/day or 3–8 movements/day with CRP > 45 mg/L predicts an ≈ 85 % likelihood of steroid failure, indicating the need for rescue therapy. 23

Rescue Therapy for Steroid Failure

If inadequate response is evident by day 3–5, initiate rescue therapy with either infliximab 5 mg/kg IV at weeks 0, 2, 6 or cyclosporine 2 mg/kg/day IV. 23

Outcomes & Prognosis

Approximately 20–30 % of patients with acute severe colitis will require colectomy during the same admission. 23
Overall mortality for acute severe colitis is about 1 %, but rises markedly in patients > 60 years old or those with significant comorbidities. 23

Management of CT‑Confirmed Diverticulitis (When Relevant)

For uncomplicated diverticulitis in immunocompetent individuals, a conservative approach without antibiotics is appropriate. 25
In immunocompromised or elderly patients with uncomplicated diverticulitis, limit antibiotic therapy to ≤ 7 days. 25
Small diverticular abscesses can be managed with antibiotics alone for 7 days. 25
Large diverticular abscesses require percutaneous drainage combined with antibiotics for 4 days. 25